Except as explicitly and expressly permitted by ISM, you are strictly prohibited from creating works or materials (including, but not limited to tables, charts, data streams, time-series variables, ...

Phase II Evaluation of Ultra-Hypofractionated Postoperative Radiation Therapy for Breast Cancer: Toxicity and Efficacy in a Single-Center Nonrandomized Prospective Study We analyzed 2,974 newly ...

Bellecapital International Ltd. increased its stake in Regeneron Pharmaceuticals by 44.1%, acquiring 6,002 additional shares. This brought its total holdings to 19,600 shares, valued at nearly $14 ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Regeneron’s investigational gene therapy has been tied to notable hearing improvements in 10 of 11 children who were treated for a rare genetic condition that causes hearing loss. “You can see ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...